SHANGHAI – The Beijing-based oncology company Beigene Co. Ltd. continuing its string of upbeat news, announcing the first human dosing of its programmed death-1 (PD-1) antibody, BGB-A317, in Australia.
SHANGHAI – New out of the gate, Suzhou Neupharma Co. Ltd., has put its first candidate, RX-108, into clinical trials. Like many companies in China with global ambitions, Neupharma is collecting its first-in-human data in Australia while it waits for its trials to get a green light in China.
SHANGHAI – The Beijing-based oncology company Beigene Co. Ltd. continuing its string of upbeat news, announcing the first human dosing of its programmed death-1 (PD-1) antibody, BGB-A317, in Australia.
SHANGHAI – Sciclone Pharmaceuticals Inc., a Foster City, Calif.-based company that brings specialty therapeutics to the China market, has secured a deal for China (including Hong Kong, Macau, Taiwan and Vietnam) with Theravance Biopharma Inc., for Vibativ (telavancin), a lipoglycopeptide antibiotic that addresses difficult-to-treat hospital-acquired infections and ventilator-assisted infections.
SHANGHAI – Sciclone Pharmaceuticals Inc., a Foster City, Calif.-based company that brings specialty therapeutics to the China market, has secured a deal for China (including Hong Kong, Macau, Taiwan and Vietnam) with Theravance Biopharma Inc., for Vibativ (telavancin), a lipoglycopeptide antibiotic that addresses difficult-to-treat hospital-acquired infections and ventilator-assisted infections.
SHANGHAI – The CFDA has an unenviable task on its hands. The agency has an enormous workload supporting the world's second-largest drug market, made more complex given it is still in a developing phase. Regulators not only have to keep up with up an 18 percent year-on-year increase in drug applications that require their review and assessment, they are simultaneously trying to construct the legal architecture necessary to regulate the industry overall.
SHANGHAI – The CFDA has an unenviable task on its hands. The agency has an enormous workload supporting the world’s second-largest drug market, made more complex given it is still in a developing phase. Regulators not only have to keep up with up an 18 percent year-on-year increase in drug applications that require their review and assessment, they are simultaneously trying to construct the legal architecture necessary to regulate the industry overall.
SHANGHAI – Fast on the heels of a major financing round in November, Beigene Co. has raised $97 million in financing, enough cash to continue to aggressively push its deep pipeline of immuno-oncology candidates in the clinic not only in China, but in global trials as well.
